SANA

SEC source: 0001562180-25-004642 · primarydocument.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004639 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004644 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004647 · primarydocument.xml · derivative · entry 1

Rosiello Robert L. · CIK 0001645041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on July 5, 2025, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. through each such date.

SEC source: 0001562180-25-004643 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-25-004641 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,828

F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.

SEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 7

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.

F7 · derivative.exercise_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.

F7 · derivative.expiration_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.

SEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.

F2 · balance_after: Includes 3,000 shares acquired on May 15, 2025 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan (the "ESPP").

SEC source: 0001562180-25-003066 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,821,113

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-25-002273 · primarydocument.xml · nonDerivative · entry 2

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,990

SEC source: 0001562180-25-002274 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,395

SEC source: 0001562180-25-002271 · primarydocument.xml · nonDerivative · entry 2

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,876,930

SEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 5

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,126

Underlying: Common Stock · 11,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F5 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F5 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-25-002273 · primarydocument.xml · nonDerivative · entry 1

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 3,001 shares acquired on May 15, 2023 and 3,000 shares acquired on each of November 15, 2023, May 15, 2024 and November 15, 2024, in each case, pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 5

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,750

Underlying: Common Stock · 3,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F4 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F4 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002274 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 8

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F5 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F5 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-25-002271 · primarydocument.xml · nonDerivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,889,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 4

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2035-03-05

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 3

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,333

Underlying: Common Stock · 53,333 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 4

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2035-03-05

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,667

Underlying: Common Stock · 41,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 7

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2035-03-05

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 6

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,667

Underlying: Common Stock · 166,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-001888 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,981

SEC source: 0001562180-25-001888 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,050

Underlying: Common Stock · 1,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024 and 2025, and the remaining restricted stock units vest in two equal installments on each of March 2, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024 and 2025, and the remaining restricted stock units vest in two equal installments on each of March 2, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-25-001888 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,471

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,541,511

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,542,511

F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,707,423

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,732,423

F1 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-000238 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,804,774

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-25-000105 · primarydocument.xml · derivative · entry 3

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F3 · derivative.exercise_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and the remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F3 · derivative.expiration_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and the remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-25-000105 · primarydocument.xml · nonDerivative · entry 2

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,946

SEC source: 0001562180-25-000105 · primarydocument.xml · nonDerivative · entry 1

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 3,000 shares acquired on November 15, 2024 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan.

SEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 6

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,100

Underlying: Common Stock · 5,100 shares

Expires 2034-12-12

F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.

F6 · derivative.exercise_date: The option vests as to 100% of the shares underlying the option on January 13, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 5

Wyrick Susan D. · CIK 0001568605 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,400

Underlying: Common Stock · 3,400 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.

F5 · derivative.exercise_date: The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F5 · derivative.expiration_date: The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-24-007283 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,790,489

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-24-006954 · primarydocument.xml · nonDerivative · entry 2

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,698,121

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 25, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.69 to $4.13, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-006954 · primarydocument.xml · nonDerivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,848,121

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 25, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.16, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-005643 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,784,551

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-24-004843 · primarydocument.xml · derivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004838 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004840 · primarydocument.xml · derivative · entry 1

Cole Douglas G. · CIK 0001486373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004839 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004844 · primarydocument.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004837 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004845 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-004841 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.